Description:
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway
alterations.
Title
- Brief Title: A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
- Official Title: A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Clinical Trial IDs
- ORG STUDY ID:
CLTT462X2101
- SECONDARY ID:
2015-003614-24
- NCT ID:
NCT02711345
Conditions
- Ovarian Neoplasms
- Non-Small-Cell Lung Carcinoma
- Melanoma
- Other Solid Tumors
Interventions
Drug | Synonyms | Arms |
---|
LTT462 | | Escalation |
Purpose
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway
alterations.
Trial Arms
Name | Type | Description | Interventions |
---|
Escalation | Experimental | | |
Expansion Group 1 | Experimental | | |
Expansion Group 2 | Experimental | | |
Expansion Group 3 | Experimental | | |
Expansion Group 4 | Experimental | | |
Eligibility Criteria
Inclusion Criteria:
- Patient (male or female) ≥12 years of age
- ECOG (Eastern Cooperative Oncology Group) performance status ≤1
- Must have progressed following standard therapy, or for whom, in the opinion of the
Investigator, no effective standard therapy exists, is tolerated or appropriate.
- Patients must be willing and able to undergo study required biopsies.
- Presence of at least one measurable lesion according to RECIST v1.1.
- Documented MAPK pathway alteration
Exclusion Criteria:
- Prior treatment with ERK inhibitors.
- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO.
- Any medical condition that would, in the investigator's judgment, prevent the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures.
- Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days
prior to the start study treatment and for the duration of the study.
- Patients with malignant disease other than that being treated in the study.
- Clinically significant cardiac disease.
Other protocol-defined exclusion criteria may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 12 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
Time Frame: | Up to 2.8 years |
Safety Issue: | |
Description: | An adverse events is defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occur after participant's signed informed consent has been obtained. A SAE is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. |
Secondary Outcome Measures
Measure: | Percentage of Participants With Overall Response Rate (ORR) |
Time Frame: | Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years) |
Safety Issue: | |
Description: | Percentage of participants with overall response rate were reported. |
Measure: | Percentage of Participants With Disease Control Rate (DCR) |
Time Frame: | Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years) |
Safety Issue: | |
Description: | Percentage of participants with disease control rate were reported. |
Measure: | Duration of Response (DOR) |
Time Frame: | Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years) |
Safety Issue: | |
Description: | DOR is defined as the time between the date of the first documented response (complete response [CR] or partial response [PR]) and the date of progression. |
Measure: | Progression Free Survival (PFS) |
Time Frame: | Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years) |
Safety Issue: | |
Description: | Median time for progression free survival was reported. |
Measure: | Overall Survival (OS) - Only for Dose Expansion Phase |
Time Frame: | Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years) |
Safety Issue: | |
Description: | Median time for overall survival, only for dose expansion phase was reported. |
Measure: | The Maximum (Peak) Observed Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Cmax) After Single Dose Administration of LTT462 |
Time Frame: | day 1, day 15 |
Safety Issue: | |
Description: | Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration expressed in mass x volume-1. |
Measure: | Area Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of LTT462 |
Time Frame: | Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1 |
Safety Issue: | |
Description: | AUClast is the area under the curve from time zero to the last measurable concentration sampling time calculated by mass * time *volume^-1 |
Measure: | The Time to Reach Maximum (Peak) Plasma, Blood, Serum, or Other Body Fluid Drug Concentration (Tmax) After Single Dose Administration of LTT462 |
Time Frame: | day 1, day 15 |
Safety Issue: | |
Description: | Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration. |
Measure: | Elimination Half-life (T1/2) of LTT462 |
Time Frame: | Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1 |
Safety Issue: | |
Description: | T1/2 is the Elimination half-life. |
Measure: | The Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of LTT462 |
Time Frame: | Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1 |
Safety Issue: | |
Description: | AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state calculated by formula amount *time * volume^-1 |
Measure: | Accumulation Ratio (Racc) of LTT462 |
Time Frame: | Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1 |
Safety Issue: | |
Description: | Racc is the accumulation ratio calculated by AUCtau ratio Day 15 versus Day 1. |
Measure: | Changes From Baseline in Relative Quantity (RQ) of Dual Specificity Phosphatase 6 (DUSP6) in Tumor Tissue and in Blood |
Time Frame: | Cycle 1 Days 1, 2, 3, 15 and 16 |
Safety Issue: | |
Description: | Assessment of Pharmacodynamic (PD) effects of LTT462 in tumor, pre- and post- treatment tumor biopsies were examined for expression of DUSP6. For assessment of PD effects in blood, levels of DUSP6 were measured in blood samples. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
Last Updated
September 19, 2019